 |
 |
Another study has just been published concluding that GDNF delivery by infusion does not cause brain lessions in monkeys. This one was conducted in Japan by independent researchers, again disproving Amgen's claims that the main safety factor for the trial halt was lesions in monkeys. Yet, Amgen has yet to make their toxicology studies public, as they had promised. The new study is supported by additional commentary from neuroscientists from Italy and the U.S. Pro-GDNF researchers have always believed the lesions in a few of the test monkeys were caused by abrupt withdrawal from extrmely high doses - much higher than any of the human subjects received. There were no lesions in this Japanese study and it supports the safety of GDNF treatment. Yet instead of being further researched and developed to bring relief and neurorestoration to PWP, it sits locked in Amgen's labs. The company executives refuse to make it available for further human studies or lease the rights to another company or agency that wants to develop it. See the full text article, and be sure to read the commentaries at the end. http://www.jstage.jst.go.jp/article/nmc/46/6/267/_pdf Linda Herman ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn